Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/12558
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTang, William W.en_US
dc.contributor.authorBauer, Kaylyn M.en_US
dc.contributor.authorBarba, Cindyen_US
dc.contributor.authorEkiz, Hüseyin Atakanen_US
dc.contributor.authorO’Connell, Ryan M.en_US
dc.date.accessioned2022-10-25T13:29:09Z-
dc.date.available2022-10-25T13:29:09Z-
dc.date.issued2022-09-
dc.identifier.urihttps://doi.org/10.3389/fimmu.2022.929677-
dc.identifier.urihttps://hdl.handle.net/11147/12558-
dc.descriptionThis work is supported by the Nation Institutes of Health 1F30CA260977 (WT), T32 Al138945 (KB), and 1F31CA261096 (CB).en_US
dc.description.abstractThe rising toll of cancer globally necessitates ingenuity in early detection and therapy. In the last decade, the utilization of immune signatures and immune-based therapies has made significant progress in the clinic; however, clinical standards leave many current and future patients without options. Non-coding RNAs, specifically microRNAs, have been explored in pre-clinical contexts with tremendous success. MicroRNAs play indispensable roles in programming the interactions between immune and cancer cells, many of which are current or potential immunotherapy targets. MicroRNAs mechanistically control a network of target genes that can alter immune and cancer cell biology. These insights provide us with opportunities and tools that may complement and improve immunotherapies. In this review, we discuss immune and cancer cell–derived miRNAs that regulate cancer immunity and examine miRNAs as an integral part of cancer diagnosis, classification, and therapy.en_US
dc.language.isoenen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Immunologyen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCancer cellsen_US
dc.subjectCell deathen_US
dc.subjectCancer immunityen_US
dc.subjectExosomesen_US
dc.subjectTumor microenvironmenten_US
dc.titlemiR-aculous new avenues for cancer immunotherapyen_US
dc.typeArticleen_US
dc.authorid0000-0001-7718-6841en_US
dc.institutionauthorEkiz, Hüseyin Atakanen_US
dc.departmentİzmir Institute of Technology. Molecular Biology and Geneticsen_US
dc.identifier.wosWOS:000868203800001en_US
dc.identifier.scopus2-s2.0-85139754126en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.3389/fimmu.2022.929677-
dc.identifier.pmid36248881-
dc.contributor.affiliationUniversity of Utahen_US
dc.contributor.affiliationUniversity of Utahen_US
dc.contributor.affiliationUniversity of Utahen_US
dc.contributor.affiliationUniversity of Utahen_US
dc.relation.issn1664-3224en_US
dc.description.volume13en_US
dc.identifier.scopusqualityQ1-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.languageiso639-1en-
item.grantfulltextopen-
item.openairetypeArticle-
crisitem.author.dept04.03. Department of Molecular Biology and Genetics-
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File Description SizeFormat 
fimmu-13-929677.pdfArticle (Makale)11.64 MBAdobe PDFView/Open
Show simple item record



CORE Recommender

Page view(s)

144
checked on Apr 15, 2024

Download(s)

60
checked on Apr 15, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.